Abstract This paper describes a selective and sensitive assay for the determination of olanzapine (OLZ) in human plasma based on liquid chromatography-tandem mass spectrometry (LC-MS/ MS). The analyte and quetiapine as internal standard (IS) were extracted from 200 mL plasma via solid phase extraction on Waters Oasis HLB cartridges. Chromatographic separation was achieved on an ACE 5C18-300 column (100 mm Â 4.6 mm, 5 mm) under isocratic conditions in a run time of 3.5 min. Mass spectrometric detection involved electrospray ionization in the positive ion mode followed by multiple reaction monitoring (MRM) of the transitions at m/z 313/256 for OLZ and m/z 384/253 for the IS. The assay was linear in the range 0.10-40.0 ng/mL with a lower limit of quantitation and limit of detection of 0.10 and 0.012 ng/mL, respectively. Intra-and inter-day precision (as coefficient of variation) and relative recovery were o5.0% and 490%, respectively. The method was successfully applied to a bioequivalence study of 5 and 10 mg OLZ disintegrating tablets in 40 healthy Indian males with reproducibility by incurred sample reanalysis in the range À7.43 to 8.07%.
Introduction
Olanzapine (OLZ), a thienobenzodiazepine derivative, is an antipsychotic drug which is highly effective in the treatment of schizophrenia and bipolar disorders 1, 2 . It is an atypical antipsycotic with less extrapyrimidal side effects and greater positive effects on cognitive deficits than typical antipsychotics 3 . This is because of its affinity for multiple receptors including dopamine D2, 5-hydroxytryptamine (5-HT) 2A and 2C, histamine H1, a-adrenergic and muscarinic receptors 4 . OLZ has been approved by the US FDA for use as monotherapy or in combination with mood stabilizers for the treatment of acute mania in bipolar disorders 1, 5 . It is available as coated tablets in dose strengths ranging from 2 to 20 mg under the brand name Zyprexa and as an orally disintegrating tablet known as Zyprexa Zydis. Following oral administration, OLZ is about 93% plasma protein bound, mainly to albumin and a-acid glycoprotein. It has an oral bioavailability of about 60% mainly due to hepatic first pass metabolism to the 10-N-glucuronide, 4 0 -N-desmethylolanzapine and olanzapine-N-oxide via uridine diphosphate glucuronyltransferase (UDPGT), cytochrome P450 (CYP) 1A2 and flavin monoxygenase (FMO), respectively. After absorption, OLZ reaches its maximum plasma concentration within 6 h and has a mean half life of about 33 h 6 . Numerous methods are described in the literature to determine OLZ in different biological fluids including GC with nitrogen phosphorous 7 and mass spectrometric detection 8 , and HPLC with electrochemical [9] [10] [11] [12] [13] [14] [15] [16] , ultraviolet [17] [18] [19] [20] [21] [22] , diode array 23 and mass spectrometric detection [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . These methods either determine OLZ alone 9, 11, 12, 14, 17, 18, 20, 21, 24, 25, 29, 33 or OLZ and its metabolites 10, 13, 15, 16, 19, 28, 37 or OLZ and other drugs particularly antipsychotics 7, 8, 19, 22, 23, 26, 27, [30] [31] [32] [34] [35] [36] . Of the methods applied to analysis of human plasma, either the chromatographic run time was long (45.0 min) 9, 12, 13, 15, 16, 18, 20, 23, 27, 35 and the plasma volume high (Z0.5 mL) 9, 15, 18, 20, 23, 27, 29, 35 or the method was too insensitive for routine application. However, the method reported by Nirogi et al. 29 based on liquid chromatographytandem mass spectrometry (LC-MS/MS) is highly sensitive with a lower limit of quantitation (LLOQ) of 100 pg/mL in human plasma and a demonstrated suitability for application to bioequivalence studies 29 . Recently, another LC-MS/MS method 37 has been applied to the determination of OLZ and N-desmethylolanzapine in human serum and cerebrospinal fluid (CSF) from patients taking OLZ. The salient features of chromatographic methods developed for OLZ in human plasma are summarized in Table 1 .
The objective of the present study was to develop and validate a selective and sensitive method for the estimation of OLZ in human plasma based on LC-MS/MS. The method uses quetiapine as internal standard (IS) and has a sensitivity equal to that of Nirogi et al. 29 using a smaller plasma volume. The method is shown to be free of interference from other antipsychotic drugs commonly taken concomitantly and was successfully applied to a bioequivalence study of 5 and 10 mg OLZ tablets in healthy volunteers under fasting and fed conditions.
Materials amd methods

Chemicals and materials
Chemicals and materials (suppliers) were as follows: Reference standard OLZ (99.5%) (Cadila Healthcare Ltd., Ahmedabad, India); quetiapine fumarate (IS, 99.2%) (Varda Biotech (P) Ltd., Mumbai, India); HPLC grade methanol and acetonitrile, analytical grade ortho-phosphoric acid, ammonia and ammonium formate (S.D. Fine Chemicals Ltd., Mumbai, India); Oasis HLB extraction cartridges (1 cc, 30 mg) (Waters Corporation, Milford, MA, USA); Control buffered (K 2 -EDTA) human plasma stored at À20 1C (Clinical Department, BA Research India Ltd., Ahmedabad, India); Mettler Toledo AG XP26DR micro balance (Greifensee, Switzerland); Eppendorf 5810 centrifuge (Hamburg, Germany); deionized water for LC-MS/MS prepared using a Milli Q water purification system (Millipore, Bangalore, India).
Instrumentation and conditions
The LC system (Shimadzu, Kyoto, Japan) consisted of an LC10ADvp pump, an autosampler (SIL-HTc) and an on-line degasser (DGU-14A). Separation was performed by isocratic elution on an ACE 5C18-300 (100 mm Â 4.6 mm, 5.0 mm) column (Chromatopak Analytical Instrumentation (India) Pvt. Ltd., Mumbai, India) with a mobile phase consisting of acetonitrile:0.01% ammonia in 2 mM ammonium formate (85:15, v/v, pH 6.6) at a flow rate of 0.9 mL/min. The autosampler was maintained at 4 1C and the injection volume was 5.0 mL. Ionization and detection of analyte and IS was performed on an API-4000 triple quadrupole mass spectrometer equipped with Turbo Ion spray s (MDS SCIEX, Toronto, Canada) operating in the positive ion mode. Quantitation was performed using multiple reaction monitoring (MRM) of the protonated precursor to product ion transitions at m/z 313.2-256.2 for OLZ and 384.2-253.2 for IS (Figs. 1a and b) . All LC and MS parameters were controlled by Analyst software version 1.4.2.
Optimized source dependant MS parameters were as follows: Gas 1 (Nebulizer), 55 psi; Gas 2 (heater), 50 psi; ion spray voltage (ISV), 5500 V; turbo heater temperature (TEM), 550 1C; entrance potential (EP), 10 V; collision activation dissociation (CAD), 6 psi; curtain gas (CUR), 30 psi. Compound dependent MS parameters viz declustering potential (DP), collision energy (CE) and cell exit potential (CXP) were, respectively 70, 35 and 15 V for OLZ and 85, 23 and 12 V for IS. Quadrupole 1 and quadrupole 3 were maintained at unit resolution and a dwell time of 600 ms was set for both OLZ and IS.
Calibration standards and quality control (QC) samples
An OLZ stock solution (100 mg/mL) in methanol was diluted with methanol:water (80:20, v/v) to produce an intermediate stock solution (800 ng/mL). This was further diluted to prepare standard and (independently) QC solutions. An IS stock solution (100 mg/mL) was also prepared in methanol and diluted with water to give an IS working solution (40.0 ng/mL). All solutions were stored at 4 1C when not in use. OLZ calibration standards (CS-1 to CS-10, 0.10, 0.20, 0.50, 1.00, 2.00, 5.00, 10.0, 20.0, 32.0 and 40.0 ng/mL), low (LQC, 0.30 ng/mL), medium (MQC-1, 16.0 ng/mL; MQC-2, 3.00 ng/mL) and high (HQC, 30.0 ng/mL) QC samples and QC samples at the lower limit of quantitation (LLOQ QC, 0.10 ng/mL) and upper limit of quantitation (ULOQ QC, 40.0 ng/mL) were prepared by spiking blank plasma with respective standard solutions (at 5% of the total volume of plasma). All CS, QC and study samples were stored at À20 1C pending analysis.
Sample preparation
Plasma samples were thawed, allowed to equilibrate at room temperature and thoroughly vortexed prior to analysis. Aliquots of study samples (190 plus 10 mL methanol:water 80:20, v/v) or CS and QC samples (200 mL) and 190 mL blank plasma were transferred into vials to which 15 mL methanol:water (80:20, v/v) and 200 mL IS working solution were added. After vortexing, 100 mL 25% orthophosphoric acid solution was added and the mixture vortexed again. Samples were then loaded onto SPE cartridges pre-conditioned with 1.0 mL methanol followed by 1.0 mL water. After centrifugation for 2 min at 1811 Â g, cartridges were washed with 2 Â 1.0 mL water and again centrifuged for 1 min at 1811 Â g. Analyte and IS were then eluted with 2 Â 0.4 mL acetonitrile:water (90:10, v/v), centrifuged for 1 min at 1811 Â g and analyzed by LC-MS/MS.
Assay validation
Assay validation was carried out according to US FDA guidelines 38 . Validation included evaluation of selectivity, interference, carryover, linearity, precision and accuracy, reinjection reproducibility, recovery, ion suppression/enhancement, matrix effects, stability and dilution integrity.
Selectivity was assessed by assay of 12 different lots of blank human plasma (including haemolysed and lipemic samples) collected with K 2 -EDTA as anticoagulant. For each lot, two replicates (190 mL) were spiked with 10 mL methanol:-water (80:20, v/v) in one case containing IS. (total 24 samples). In addition, a system suitability sample (SSS) with the same concentration as CS-2 and two replicates of CS-1 were prepared. The blank human plasma used for spiking these samples was chosen from one of the 12 lots. The acceptance criterion was that at least 90% of samples should be free from any interference at the retention times of analyte and IS.
Potential interference from acetaminophen, aspirin, caffeine, cetirizine, chlorpheniramine maleate, ibuprofen and pseudoephedrine were evaluated. Additionally, the antipsychotics, clozapine, risperidone and aripiprazole, were studied for ion suppression/enhancement, analytical recovery (precision and accuracy) and chromatographic interference at the MRM transitions of analyte and IS. Their stock solutions (100 mg/mL) were prepared in methanol and diluted in methanol:water (80:20, v/v) to 20.0 mg/mL working solutions. They were then analyzed in triplicate under the same conditions as the LQC and HQC samples along with freshly prepared CS and two sets (8 samples) of HQC, MQC-1, MQC-2 and LQC. The acceptance criteria was that the accuracy should be in the range 85-115%. MRM transitions (positive ionization mode) for clozapine (327.1/270.2), risperidone (411.3/191.2) and aripiprazole (448.0/285.2) were studied.
Carryover was assessed by injecting the following sequence of samples; double blank plasma, two LLOQ samples, double blank plasma, an ULOQ sample, double blank plasma, an ULOQ sample and finally double blank plasma.
Linearity was determined by construction of six calibration curves based on peak area ratios at ten non-zero concentrations. Each calibration curve was analyzed individually by least squares weighted (1/x 2 ) linear regression. A correlation coefficient (r 2 )40.99 was desirable for all calibration curves. The lowest standard on the calibration curve was accepted as the LLOQ if the analyte response was at least 10 times more than that of blank plasma.
To determine intra-day accuracy and precision, a calibration curve and six replicates of LLOQ QC, LQC, MQC-2, MQC-1, HQC and ULOQ QC were analysed on the same day. Inter-day accuracy and precision were assessed by analyzing three batches of samples on three consecutive days. The deviation from the nominal concentration is required to be o715% except at the LLOQ where 720% is allowed. Similarly, accuracy should be within 715% except at the LLOQ where it can be within 720% of nominal concentrations. Reinjection reproducibility was performed by reinjecting one complete validation batch.
Relative recovery (RE), matrix effects (ME) and process efficiency were assessed as recommended by Matuszewski et al. 39 . All three parameters were evaluated by assay of six replicates of HQC, MQC-1, MQC-2 and LQC samples. RE was calculated by comparing the mean area responses of samples spiked before extraction with those of samples spiked after extraction at each QC level. The recovery of IS was estimated in the same way. Absolute ME were assessed by comparing the mean area responses of samples spiked after extraction with those of standard solutions in mobile phase. Overall ''process efficiency'' (PE, %) was calculated as (ME Â RE)/100. In addition, the effect of the plasma matrix was checked using eight different lots of K 2 -EDTA anticoagulated plasma including haemolysed and lipemic samples. For each lot, four samples at LQC and HQC levels were spiked after extraction and checked for accuracy and precision. The effect of the matrix on ion suppression was evaluated by post-column infusion 40 at 5.0 mL/min of a standard solution containing 16.0 ng/mL OLZ and 40.0 ng/ mL IS in mobile phase via a 'T' connector employing a Harvard infusion pump (Harvard Bioscience, USA). Aliquots (5.0 mL) of extracted blank plasma (without OLZ and IS) were then injected and chromatograms acquired. Any reduction in the baseline on injection of the blank plasma was taken to indicate ion suppression whereas a peak at the retention time of either OLZ or IS ws taken to indicate ion enhancement.
Stability was evaluated by comparing concentrations of LQC and HQC samples subjected to various conditions with those of freshly prepared samples. Samples were considered stable if deviation from nominal values was o710.0%. Stock solutions of OLZ and IS were checked for short term stability at room temperature and long term stability at 4 1C. Bench top stability, processed sample stability at room temperature and at 4 1C, freeze-thaw stability and long term stability at À20 1C were performed by assay of six replicates. To meet acceptance criteria, concentrations in at least 2/3 of QC samples should remain within 715% with accuracy in the range 85-115%.
Dilution integrity was assessed by assay of five samples with analyte concentrations above the ULOQ i.e., at 200 ng/mL and at the HQC level. Six replicates of samples after ten-fold dilution (20.0 and 3.0 ng/mL) were prepared and their OLZ concentrations calculated by applying the dilution factor of 10 to concentrations obtained from the calibration curve.
Bioequivalence study design
The design of the study comprised an open label, randomized, two period, two treatment, two sequence, crossover, balanced, single dose, evaluation of the relative oral bioavailability of a 5 mg OLZ disintegrating tablet from a sponsor company (test) and a 5 mg OLZ disintegrating tablet (ZYPREXA s ZYDIS s ) from Eli Lilly and Co., Indianapolis, Indiana 46285, USA (reference) in 40 healthy Indian males under fasting and fed conditions. The study also included evaluation of a 10 mg OLZ disintegrating tablet from a Sponsor company (test) and a 10 mg OLZ disintegrating tablet (ZYPREXA s VELOTAB TM ) from Eli Lilly and Co., Netherlands (reference) in 40 healthy Indian males under fasting conditions. All participants were informed of the aims and risks of the study and gave written consent. Inclusion criteria were; age 18-45 years, body mass index 18.5-30.0 kg/height 2 , and no abnormalities on general physical examination, electrocardiogram and laboratory tests (hematology, blood and urine chemistry and immunological tests). Exclusion criteria were; allergy to OLZ, alcoholism, smoking, diabetes, psychosis, and any disease which could compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory or central nervous systems. The protocol was approved and subject to review by the relevant Institutional Ethics Committee. All procedures in dealing with human subjects were based on the International Conference on Harmonization, E6 Good Clinical Practice (ICH, E6 GCP) guidelines 41 . Subjects in fasting studies were required to fast for 10 h before administration of drug. Subjects in fed studies were given a high fat, high (969) calorie breakfast (consisting of 200 mL milk with 16 g sugar, 80 g black gram, two slices bread and butter and two cheese cutlets) 30 min prior to drug adminstration. Blood samples were collected in vacutainers containing K 2 -EDTA anticoagulant before and at 1-10, 12, 16, 24, 36, 48, 72, 96, 120, 144 and 168 h after administration of drug. Plasma obtained by centrifugation at 1811 Â g and 4 1C for 15 min was stored at À20 1C until assayed. An incurred sample reanalysis (ISR) was also conducted for all three studies by computerized random selection of 442 samples (10% of the total study sample) with concentrations near the C max or during the elimination phase. The results were compared with corresponding values obtained earlier for the same sample using the same procedure. The percent change should not be more than 720% 42 where
Change ð%Þ ¼ ½ðRepeat valueÀInitial valueÞ= Mean of repeat and initial values Â 100% ð1Þ
Statistical analysis
Pharmacokinetic parameters for OLZ were estimated by noncompartmental analysis using WinNonlin software version 5.2.1 (Pharsight Corporation, Sunnyvale, CA, USA). The C max values and the time to reach maximum plasma concentration (T max ) were determined directly from plasma concentration-time curves. Area under plasma concentration-time curves from time 0 to 168 h (AUC 0-168 ) was calculated using the linear trapezoidal rule. AUC 0-N was calculated as AUC 0-168 þC t /k el , where C t is the last plasma concentration measured and k el is the elimination rate constant determined by linear regression of the logarithm linear part of the plasma concentration-time curve. The T 1/2 of OLZ was calculated as ln 2/k el . To determine whether test and reference formulations were pharmacokinetically bioequivalent, the mean and 90% confidence intervals (CI) of log transformed C max , AUC 0-168 , AUC 0-N and their ratios (test/reference) were determined using SAS s software version 9.1.3 (SAS Institute Inc., Cary, NC, USA). The formulations were considered bioequivalent if the differences between the compared parameters were not significantly different (PZ0.05) and the 90% CIs for these parameters fell within the range 0.8-1.25.
Results and discussion
Method development
The objective of the present work was to develop and fully validate an LC-MS/MSmethod for the determination of OLZ in human plasma with sensitivity adequate to monitor the concentration of OLZ for least five half lives after a therapeutic dose. To realize this aim, the extraction procedure, mass spectrometry and chromatographic conditions were optimized. The ESI was operated in the positive ion mode as both OLZ and IS are basic in nature. OLZ and IS gave predominant, singly charged protonated precursor [MþH] þ ions at m/z 313.2 and 384.2, respectively in Q1 full scan spectra. Furthermore, the most abundant ion in the product ion mass spectra of OLZ was at m/z 256.2, resulting from cleavage of the piperazine ring to the neutral fragment, CH 3 NHCH¼ CH 2 . As previously reported 43 , other characteristic fragments were observed at m/z 282.4 and 213.0 attributed to formation of CH 3 NH 2 and elimination of the piperazine ring, respectively. The proposed fragmentation pathway of OLZ is depicted in Fig. 2a .
For quetiapine, the most stable and reproducible product ion at m/z 253.2 arises from cleavage of the piperazine ring 44 . The other product ion at m/z 279.4 is due to breaking of two C-N bonds from the precursor ion to eject the fragment, (HOCH 2 CH 2 OCH 2 CH 2 NH 2 ) m/z 105, as shown in Fig. 2b . To attain an ideal Taylor cone and a better impact on spectral response, the nebulizer gas (gas 1) pressure was optimized at 55 psi. Fine tuning of the nebulizer and CAD gas was carried out to obtain a consistent and stable response. Ion spray voltage and temperature did not affect analyte response and were maintained at 5500 V and 550 1C, respectively. A dwell time of 600 ms was found adequate for OLZ and IS and no cross talk was observed between the MRMs of analyte and IS.
Chromatographic conditions including mobile phase selection, flow rate, column type and injection volume were optimized. Mobile phases containing different ratios (5:95, 10:90, 15:85, 20:80 and 30:70, v/v) of water-methanol/acetonitrile together with either formic acid, ammonia (0.01-0.005%), ammonium trifluoroacetate, ammonium acetate or ammonium formate buffers in varying strengths (2-20 mM) at flow rates of 0.5-1.0 mL/min were evaluated. A number of columns including Hypurity C8 (50 mm Â 4.6 mm, 5 mm), Hypurity cyano (50 mm Â 4.6 mm, 5 mm), Beta basic cyano (100 mm Â 2.1 mm, 5 mm), BDS Hypersil C18 (50 mm Â 4.6 mm, 5 mm) and ACE 5C18-300 (100 mm Â 4.6 mm, 5 mm) were also evaluated. Finally it was found that the ACE 5C18-300 column with a mobile phase consisting of acetonitrile : 0.01% ammonia in 2 mM ammonium formate solution (pH 6.6) (85:15, v/v) at a flow rate of 0.9 mL/min provided the best combination of efficiency, peak shape and resolution within 3.0 min. Under these conditions, the retention times for OLZ and IS were 2.36 and 2.05 min, respectively with a reproducibility for the OLZ retention time (as CV %) of r1.3% for 100 injections on the same column. Capacity factors for OLZ and IS based on a solvent front of 1.1 min were 0.86 and 1.15, respectively with a selectivity factor (a) of 0.74. The number of theoretical plates for OLZ and IS were 660 and 620, respectively with a resolution factor of 0.9.
In terms of the choice of IS, a deuterated analogue is preferable but was not available. Therefore an atypical antipsychotic belonging to the same class of dibenzothiazepines was selected in the present work. Quetiapine showed similar chromatographic behavior and did not affect analyte recovery, sensitivity or ion suppression.
As part of the investigation into the extraction efficiency of OLZ from plasma, the effect of the anticoagulants K 3 EDTA, K 2 EDTA and Na-heparin was evaluated. Chin et al. 28 extensively studied the potential matrix effects of anticoagulants and lipemia on an LC-MS/MS assay for OLZ and its metabolite. As a result, they suggested that K 3 EDTA and Na-heparin should be avoided, especially for lipemic samples. Consistent with their observation, the best result was obtained using K 2 EDTA as anticoagulant.
As is clear from 20 , ethyl acetate-n-hexane-isopropanol 23 and diethyl ether-dichloromethane 29 has provided quantitative recoveries. Nevertheless, LLE sometimes required an additional back extraction step under acidic conditions to produce clean extracts 20, 23 . In the present work, protein precipitation (PP) using methanol and acetonitrile was first evaluated but gave poor recovery and considerable ion suppression. LLE under alkaline conditions using different solvents (diethyl ether, n-hexane, dichloromethane, methyl tert-butyl ether and ethyl acetate) alone and in combination was then evaluated 23, 27, 29 but, although diethyl ether-dichloromethane gave promising results, the recovery was not consistent at all QC levels. As regards the previous use of SPE, Oasis MCX columns under acidic conditions (citric acid) gave quantitative recovery of psychotropic drugs and their metabolites 28, 35 and Raggi et al. 13 obtained a recovery of OLZ of 97.9% using Oasis HLB under neutral conditions. Accordingly SPE on Oasis columns with hydrophilic-lipophilic balance (HLB) were evaluated under both acidic and neutral conditions and shown to provide quantitative recovery with minimum matrix effects in both cases. However, given that a slightly higher recovery was obtained using an acidic media (100 mL 25% orthophosphoric acid), the latter conditions were used in the present work.
System suitability and carryover
During assay validation, the precision (CV, %) of a system suitability test was found to be in the range 0.11-0.54% for retention time and 1.6-2.2% for the area response of OLZ and IS. The signal-to-noise ratio for system performance was Z25 for both analyte and IS. Carryover was shown to be negligible (r0.51%) in that no enhancement in response was observed in extracted blank plasma (without IS and analyte) after subsequent injection of the ULOQ standard at the retention times of OLZ or IS. 
Selectivity and interference
All samples were found to be free of interference from endogenous substances in plasma as shown in Figs. 3a-c. Similarly, no interference was observed from commonly used medications such as acetaminophen, aspirin, caffeine, cetirizine, chlorpheniramine maleate, ibuprofen and pseudoephedrine as shown in Fig. 3d . In addition, the three antipsychotic drugs (clozapine, risperidone and aripiprazole) did not interfere in the determination of OLZ. This was because, although their retention times were 2.72, 2.60 and 3.21 min, respectively, their MRM transitions were different from that of OLZ. Accuracy (%) for OLZ at all QC levels was in the range 93.4-101.4%.
Linearity, sensitivity, accuracy and precision
All six calibration curves were linear over the concentration range 0.10-40.0 ng/mL with correlation coefficients rZ0.9996. The equation of the calibration curve was y¼ (0.119670.0106)xÀ (0.000770.0001) where y is analyte/IS peak area ratio and x is analyte concentration. Accuracy (%) and precision (CV, %) of calibration standards were 97.0-103.1% and 1.2-3.9%, respectively. The LLOQ was 0.10 ng/mL at a signal-to-noise ratio Z25 and the limit of detection (LOD) was 0.012 ng/mL. Intra-day precision and accuracy (Table 2 ) were 0.6-4.3% and 93.3-102.3%, respectively. Inter-day precision and accuracy were 1.9-4.6% and 96.7-102.8%, respectively.
Recovery and matrix effects
The relative recoveries, absolute matrix effects and process efficiencies for OLZ and IS are presented in Table 3 . The relative recovery of analyte is the ''true recovery'' since it is calculated by comparing the response (analyte/IS) of samples spiked before extraction with the response of samples spiked after extraction. The process efficiency/absolute recovery obtained for OLZ and IS was Z88% at all QC levels. Furthermore, relative matrix effects which compares the precision (CV, %) between different lots of plasma samples spiked after extraction varied from 0.3 to 3.6% for OLZ at the LOQ and HQC levels (Table 4) . Postcolumn analyte infusion chromatograms (Fig. 4) indicate there was no ion suppression or enhancement at the retention times of OLZ and IS. The average matrix factor value calculated as the response of post spiked samples divided by the response of neat solutions in mobile phase at the LLOQ level was 0.98 indicating suppression was only 2%. 3.6. Stability, dilution integrity and ruggedness The stock solution of OLZ was stable for 6 h at room temperature and for 41 days at 4 1C. The intermediate stock solution of OLZ was stable for 24 h at room temperature and for 15 days at 4 1C with percent changes of 0.9 and 2.7%, respectively. OLZ was found to be stable in plasma for up to 24 h at room temperature and during six freeze-thaw cycles. Table 5 . The precisions for ten-fold dilutions of 5 Â ULOQ (20.0 ng/mL) and HQC (3.00 ng/mL) were 0.5 and 1.2%, respectively with accuracies of 101.6 and 103.2%, respectively. These values are within the acceptance limits of 15% for precision and 85-115% for accuracy.
Method ruggedness was evaluated for QC samples by (a) reanalysis on a different column of the same make and (b) reanalysis by a different analyst. Precision (CV, %) and accuracy (%) for reanalysis on different columns were in the ranges 1.6-2.8% and 94.9-99.2%, respectively. Corresponding ranges for reanalysis by a different analyst were 1.9-3.2% and 95.8-101.6%, respectively.
Bioequivalence study
All subjects completed the studies with no evidence of adverse events. Fig. 5 shows plasma concentration-time profiles of OLZ in healthy subjects under fasting and fed conditions. The method allowed plasma concentrations to be monitored for up to 168 h. In total, 6183 samples were successfully analyzed with precision and accuracy within acceptable limits. Table 6 compares pharmacokinetic parameters for the 10 mg tablet with values reported in a similar study 45 . C max and T max values were marginally lower than in the previous study while AUC 0-t , AUC 0-N and T 1/2 values were somewhat higher. This may be due to differences in genetics, race, age and gender (body size and muscle mass) of the study subjects or to differences in the type of food consumed. The effect of food was negligible in the study of the 5 mg tablet. Comparison of the two dose strengths (5 and 10 mg) reveals dose-dependent pharmacokinetics. The bioequivalence statistics of the two formulations are summarized in Table 7 . No statistically significant differences were found in any parameter between the two formulations. The mean log-transformed ratios of the parameters and their 90% CIs were all within the required ranges confirming the bioequivalence of the test and reference products. The percent change in the randomly selected samples for incurred sample (assay reproducibility) reanalysis (Fig. 6 ) was in the range À7.43 to 8.07%. This authenticates the reproducibility and ruggedness of the method.
Comparison with previous methods
The method reported here has high sensitivity with the use of only 200 mL plasma samples. Moreover, the total analysis time (including extraction and chromatography) is the shortest of all reported methods except one 29 . Also, the on-column loading of OLZ at the ULOQ is only 50 pg/injection which is about 12 times lower than for the equally sensitive method reported by Nirogi et al. 29 . Additionally, the bioequivalence study was conducted in both fasting and fed conditions. Incurred sample reanalysis, which has now become mandatory for clinical and non-clinical studies proves the reproducibility of the proposed method in samples from healthy subjects. A detailed comparison of the salient features of the present method with those of reported asays for OLZ in human plasma is given in Table 8 .
Conclusions
The objective of this work was to develop a selective and sensitive method for the determination of olanzapine in human plasma suitable for pharmacokinetic studies. The method was shown to be free of interference from other antipsychotic drugs namely clozapine, risperidone and aripiprazole and from other commonly used medications. Moreover, the sensitivity was sufficient to monitor olanzapine plasma concentration for at least five half lives after a therapeutic dose with good intra-and inter-day accuracy and precision. In fact, the maximum on-column loading was Table 7 Comparison of treatment ratios and 90% CIs of natural log(Ln)-transformed parameters for 5 mg and 10 mg olanzapine test and reference formulations under fasting and fed condition. considerably less than in other reported procedures which contributes to maintaining the efficiency and life of the column. Finally the simplicity of sample preparation and the short chromatographic run time of 3.5 min gives the method the capability for high sample throughput. The proposed method provides the means to carry out a wide range of pharmacokinetic/bioequivalence studies.
